BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 38541077)

  • 1. BRAF V600E Mutation in Malignant Melanoma-A Romanian Research Experience.
    Avădănei ER; Căruntu ID; Nucă I; Balan R; Lozneanu L; Giusca SE; Amalinei C
    Medicina (Kaunas); 2024 Feb; 60(3):. PubMed ID: 38541077
    [No Abstract]   [Full Text] [Related]  

  • 2. Multi-center evaluation of the novel fully-automated PCR-based Idylla™ BRAF Mutation Test on formalin-fixed paraffin-embedded tissue of malignant melanoma.
    Melchior L; Grauslund M; Bellosillo B; Montagut C; Torres E; Moragón E; Micalessi I; Frans J; Noten V; Bourgain C; Vriesema R; van der Geize R; Cokelaere K; Vercooren N; Crul K; Rüdiger T; Buchmüller D; Reijans M; Jans C
    Exp Mol Pathol; 2015 Dec; 99(3):485-91. PubMed ID: 26407762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological Characteristics of BRAF V600E Mutated Melanomas in the Dalmatian Region of Croatia.
    Bezić J; Kuret S; Vrbičić B; Smolić J; Borić I; Škifić I; Ledina D; Božić J
    Acta Dermatovenerol Croat; 2019 Dec; 27(4):225-230. PubMed ID: 31969234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody.
    Capper D; Preusser M; Habel A; Sahm F; Ackermann U; Schindler G; Pusch S; Mechtersheimer G; Zentgraf H; von Deimling A
    Acta Neuropathol; 2011 Jul; 122(1):11-9. PubMed ID: 21638088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymph node metastases of melanoma: challenges for BRAF mutation detection.
    Chen G; Dudley J; Tseng LH; Smith K; Gurda GT; Gocke CD; Eshleman JR; Lin MT
    Hum Pathol; 2015 Jan; 46(1):113-9. PubMed ID: 25456393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.
    Long GV; Wilmott JS; Capper D; Preusser M; Zhang YE; Thompson JF; Kefford RF; von Deimling A; Scolyer RA
    Am J Surg Pathol; 2013 Jan; 37(1):61-5. PubMed ID: 23026937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical neuropathology practice news 2-2012: BRAF V600E testing.
    Capper D; Berghoff AS; von Deimling A; Preusser M
    Clin Neuropathol; 2012; 31(2):64-6. PubMed ID: 22385786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective evaluation of two screening methods for molecular testing of metastatic melanoma: Diagnostic performance of BRAF V600E immunohistochemistry and of a NRAS-BRAF fully automated real-time PCR-based assay.
    Vallée A; Denis-Musquer M; Herbreteau G; Théoleyre S; Bossard C; Denis MG
    PLoS One; 2019; 14(8):e0221123. PubMed ID: 31415669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of BRAF V600E mutational status in capsular nevi of sentinel lymph nodes in patients with primary cutaneous melanoma.
    Siroy AE; Aung PP; Torres-Cabala CA; Tetzlaff MT; Nagarajan P; Milton DR; Curry JL; Ivan D; Prieto VG
    Hum Pathol; 2017 Jan; 59():48-54. PubMed ID: 27666765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective immunohistochemical analysis of BRAF V600E mutation in melanoma.
    Thiel A; Moza M; Kytölä S; Orpana A; Jahkola T; Hernberg M; Virolainen S; Ristimäki A
    Hum Pathol; 2015 Feb; 46(2):169-75. PubMed ID: 25442222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid BRAF mutation tests in patients with advanced melanoma: comparison of immunohistochemistry, Droplet Digital PCR, and the Idylla Mutation Platform.
    Bisschop C; Ter Elst A; Bosman LJ; Platteel I; Jalving M; van den Berg A; Diepstra A; van Hemel B; Diercks GFH; Hospers GAP; Schuuring E
    Melanoma Res; 2018 Apr; 28(2):96-104. PubMed ID: 29232304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testing.
    Boursault L; Haddad V; Vergier B; Cappellen D; Verdon S; Bellocq JP; Jouary T; Merlio JP
    PLoS One; 2013; 8(8):e70826. PubMed ID: 23976959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor cellularity as a quality assurance measure for accurate clinical detection of BRAF mutations in melanoma.
    Dudley JC; Gurda GT; Tseng LH; Anderson DA; Chen G; Taube JM; Gocke CD; Eshleman JR; Lin MT
    Mol Diagn Ther; 2014 Aug; 18(4):409-18. PubMed ID: 24604154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of BRAF(V600E) mutations in giant congenital melanocytic nevi in a Chinese population.
    Wu D; Wang M; Wang X; Yin N; Song T; Li H; Yu J; Wang DM; Zhao Z
    Am J Dermatopathol; 2011 Jun; 33(4):341-4. PubMed ID: 21430505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular platforms utilized to detect BRAF V600E mutation in melanoma.
    Curry JL; Torres-Cabala CA; Tetzlaff MT; Bowman C; Prieto VG
    Semin Cutan Med Surg; 2012 Dec; 31(4):267-73. PubMed ID: 23174497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRAF V600K vs. BRAF V600E: a comparison of clinical and dermoscopic characteristics and response to immunotherapies and targeted therapies.
    Zengarini C; Mussi M; Veronesi G; Alessandrini A; Lambertini M; Dika E
    Clin Exp Dermatol; 2022 Jun; 47(6):1131-1136. PubMed ID: 35080260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular evaluation of BRAF V600 mutation and its association with clinicopathological characteristics: First findings from Indian malignant melanoma patients.
    Ahmad F; Avabhrath N; Natarajan S; Parikh J; Patole K; Das BR
    Cancer Genet; 2019 Feb; 231-232():46-53. PubMed ID: 30803557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Utility and evaluation of immunohistochemical detection of BRAF V600E mutation in melanoma].
    Lyu JJ; Kong YY; Cai X; Shen XX; Lu YW; Ren M
    Zhonghua Bing Li Xue Za Zhi; 2017 Aug; 46(8):548-552. PubMed ID: 28810295
    [No Abstract]   [Full Text] [Related]  

  • 19. A comparison of immunohistochemical and molecular methods used for analyzing the BRAF V600E gene mutation in malignant melanoma in Taiwan.
    Huang WK; Kuo TT; Wu CE; Cheng HY; Hsieh CH; Hsieh JJ; Shen YC; Hou MM; Hsu T; Chang JW
    Asia Pac J Clin Oncol; 2016 Dec; 12(4):403-408. PubMed ID: 27488807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of cell-free circulating BRAF
    Calbet-Llopart N; Potrony M; Tell-Martí G; Carrera C; Barreiro A; Aguilera P; Podlipnik S; Puig S; Malvehy J; Puig-Butillé JA
    Br J Dermatol; 2020 Feb; 182(2):382-389. PubMed ID: 31102256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.